Correlation Between Catalyst Pharmaceuticals and Royalty Management

Can any of the company-specific risk be diversified away by investing in both Catalyst Pharmaceuticals and Royalty Management at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Catalyst Pharmaceuticals and Royalty Management into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Catalyst Pharmaceuticals and Royalty Management Holding, you can compare the effects of market volatilities on Catalyst Pharmaceuticals and Royalty Management and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Catalyst Pharmaceuticals with a short position of Royalty Management. Check out your portfolio center. Please also check ongoing floating volatility patterns of Catalyst Pharmaceuticals and Royalty Management.

Diversification Opportunities for Catalyst Pharmaceuticals and Royalty Management

0.65

Correlation Coefficient

Catalyst Pharmaceuticals  Royalty Management

Poor diversification

The 3 months correlation between Catalyst and Royalty is 0.65. Overlapping area represents the amount of risk that can be diversified away by holding Catalyst Pharmaceuticals and Royalty Management Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Royalty Management and Catalyst Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Catalyst Pharmaceuticals are associated (or correlated) with Royalty Management. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Royalty Management has no effect on the direction of Catalyst Pharmaceuticals i.e., Catalyst Pharmaceuticals and Royalty Management go up and down completely randomly.

Pair Corralation between Catalyst Pharmaceuticals and Royalty Management

Given the investment horizon of 90 days Catalyst Pharmaceuticals is expected to generate 1.29 times less return on investment than Royalty Management. But when comparing it to its historical volatility, Catalyst Pharmaceuticals is 2.06 times less risky than Royalty Management. It trades about 0.11 of its potential returns per unit of risk. Royalty Management Holding is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  103.00  in Royalty Management Holding on September 16, 2024 and sell it today you would earn a total of  4.00  from holding Royalty Management Holding or generate 3.88% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Catalyst Pharmaceuticals  vs.  Royalty Management Holding

Catalyst Pharmaceuticals

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Catalyst Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Catalyst Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Royalty Management

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Royalty Management Holding are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very abnormal fundamental indicators, Royalty Management displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Catalyst Pharmaceuticals and Royalty Management

The main advantage of trading using opposite Catalyst Pharmaceuticals and Royalty Management positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Catalyst Pharmaceuticals position performs unexpectedly, Royalty Management can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Royalty Management will offset losses from the drop in Royalty Management's long position.

The idea behind Catalyst Pharmaceuticals and Royalty Management Holding pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.